Introduction
============

For patients with unresectable malignant hilar biliary strictures (UMHBS), palliative biliary drainage is the treatment of choice. This can be performed surgically, percutaneously, or endoscopically. Although endoscopic transpapillary biliary drainage is the preferred method because of its minimal invasiveness, ongoing controversy exists in the selection of appropriate devices, the range of biliary drainage, and the method of stent deployment.

There are two methods of deploying bilateral self-expandable metal stents (SEMS) endoscopically: side-by-side (SBS) and stent-in-stent (SIS). Using the SBS method, two SEMS are deployed in the right and left hepatic ducts parallel to each other, enabling selective reintervention. On the other hand, using the SIS method, the second SEMS is deployed in the contralateral hepatic duct through the mesh of the first SEMS. This enables stent placement that is fitted to the bile duct structure and reduces risk of excessive compression in the hilum. To date, there have been only two retrospective studies comparing outcomes between SBS and SIS methods, and the results have been controversial [@JR1351-1] [@JR1351-2] .

Endoscopic deployment of multiple SEMS (≥ 3) using the SIS method was reported to treat high-grade UMHBS [@JR1351-3] [@JR1351-4] . This treatment was performed as a reasonable option to control cholangitis and preserve the functional volume of the liver as much as possible prior to chemotherapy. The idea is very attractive; however, problems remain regarding technical difficulties with initial stent deployment and reintervention for stent occlusion. To overcome these problems, we deployed multiple SEMS using a combination of SBS and SIS methods to treat high-grade UMHBS [@JR1351-5] . In this study, we reviewed a series of the cases treated with this technique and clarified its usefulness.

Case reports
============

The study was approved by the ethical committee of Japan Community Health Care Organization Kobe Central Hospital and registered in University Hospital Medical Information Network Clinical Trials Registry (UMIN000033685).

From August 2015 to March 2018, 11 consecutive patients with high-grade UMHBS (mean age: 76 years, range: 53 -- 88 years, male/female: 5/6, Bismuth-Corlette classification IIIa/IV: 7/4) underwent endoscopic deployment of multiple SEMS (≥ 3) using a combination of SBS and SIS methods. The cases involved six cholangiocarcinomas, three gallbladder carcinomas, one cholangiocellular carcinoma, and one hepatocellular carcinoma. Pathology was confirmed cytologically and/or histologically in all patients preoperatively. The patients' characteristics are shown in [Table 1](#TB1351-1){ref-type="table"} .

###### Patient characteristics.

                                                                **Data**
  ------------------------------------------------------------- --------------------------
  Number of patients                                            11
  Age (yr), mean                                                76 (range 53 -- 88)
  Gender (n, %)                                                 
  Male                                                          5, 45.5
  Female                                                        6, 54.5
  Diagnosis (n, %)                                              
  Cholangiocarcinoma                                            6, 545
  Gall bladder carcinoma                                        3, 27.3
  Cholangiocellular carcinoma                                   1, 9.1
  Hepatocellular carcinoma                                      1, 9.1
  Type of stenosis [1](#FN1351-1){ref-type="table-fn"} (n, %)   
  IIIa                                                          7, 63.6
  IV                                                            4, 36.4
  T-Bil (mg/dL), mean                                           15 (range 2 -- 27)
  ALP (U/L), mean                                               1738 (range 554 -- 2687)
  Follow-up period (days), mean                                 184 (range 37 -- 558)

T-Bil, total bilirubin; ALP, alkaline phosphatase.

Bismuth-Corlette classification

. SEMS deployment
-----------------

###### 

**Video 1** After selective cannulation using a 0.025-inch guide wire, the SEMS were deployed in the right posterior sectoral duct and the left hepatic duct using the SBS method. Next, a 0.025-inch guide wire was introduced into the right anterior sectoral duct through the mesh of the SEMS on the right side. Then, the mesh of the stent was dilated with a 6-mm balloon, the guide wire was exchanged for a 0.035-inch stiff guide wire, and the delivery system was introduced. Finally, another SEMS was deployed in the right anterior sectoral duct using the SIS method.

After initial drainage with endoscopic biliary stenting and/or endoscopic nasobiliary drainage, SEMS were typically deployed as follows. After selective cannulation using a tapered-tip catheter (MTW Endoskopie, Wesel, Germany) and a 0.025-inch guide wire (VisiGlide 2; Olympus Medical Systems, Tokyo, Japan), two 6-Fr stent delivery systems (Zilver 635 Biliary Self-Expanding Stent, 8-mm stent diameter; Cook Medical, Tokyo, Japan) were simultaneously inserted through the working channel of a therapeutic duodenoscope (TJF-260V; Olympus Medical Systems, Tokyo, Japan). They were positioned such that one was in the right posterior sectoral duct and one in the left hepatic duct. The SEMS were deployed using the SBS method with the distal stent markers aligned within the duct to facilitate selective reintervention. Next, a 0.025-inch guide wire was introduced into the right anterior sectoral duct through the mesh of the SEMS on the right side. Then, the mesh of the stent was dilated with a 6-mm balloon (REN; Kaneka Medix, Osaka, Japan), the guide wire was exchanged for a 0.035-inch stiff guide wire (Wrangler; Piolax, Kanagawa, Japan), and the delivery system was introduced. Finally, another SEMS was deployed in the right anterior sectoral duct using the SIS method ( [Fig. 1a](#FI1351-1){ref-type="fig"} , [Fig. 1b](#FI1351-1){ref-type="fig"} , [Fig. 1c](#FI1351-1){ref-type="fig"} , [Fig. 1d](#FI1351-1){ref-type="fig"} , [Fig. 1e](#FI1351-1){ref-type="fig"} , [Fig. 1f](#FI1351-1){ref-type="fig"} , [Video 1](#ME1351-1){ref-type="media"} ).

![After selective cannulation using a 0.025-inch guide wire, the SEMS were deployed in the right posterior sectoral duct and the left hepatic duct using the SBS method. **d** After balloon dilation and exchange for a 0.035-inch stiff guide wire, the stent delivery system was introduced into the right anterior sectoral duct through the mesh of the SEMS on the right side. **e, f** Another SEMS was deployed in the right anterior sectoral duct using the SIS method.](10-1055-a-0849-9334-i1351ei1){#FI1351-1}

Outcome measurements
--------------------

We retrospectively reviewed the following outcomes: 1) technical and clinical success rates; 2) reinterventions; 3) stent patency; and 4) early (≤ 30 days) and late (\> 30 days) adverse events (AEs). Technical success was defined as successful deployment of multiple SEMS (≥ 3) at the intended position. Clinical success was defined as a decrease of more than 50 % in serum total bilirubin (T-Bil) level within 1 month after SEMS deployment compared with the pre-intervention level [@JR1351-6] . Stent occlusion was defined as recurrence of biliary obstruction and jaundice and/or evidence of cholestasis confirmed by computed tomography, requiring biliary reintervention. Reinterventions were evaluated by type of treatment and feasibility of treatment for both liver lobes. Stent patency was defined as the period between SEMS deployment and stent occlusion. Any death before stent occlusion was treated as censored data when calculating stent patency. Follow-up was performed until May 1, 2018.

Statistical analysis
--------------------

Continuous variables were described using mean and range, and categorical variables were expressed as proportions. Wilcoxon signed-rank test was used to compare laboratory parameters before and after deploying SEMS. A *P* value \< .05 was considered statistically significant. Stent patency was analyzed by the Kaplan-Meier method.

Demographic data and outcomes
-----------------------------

Demographic data on and outcomes for each patient are shown in [Table 2](#TB1351-2){ref-type="table"} . The technical success rate was 11/11. More than three SEMS were successfully deployed at the intended position in all cases. The clinical success rate was also 11/11. The mean serum T-Bil level decreased significantly 1 month after deploying SEMS, and there was no exacerbation in any patients after deploying SEMS. Stent occlusion was recognized in four patients (mean: 134 days, range: 28 -- 232). Causes of stent occlusion were tumor ingrowth in two cases, tumor overgrowth in one, and biliary sludge in one. Tumor ingrowth and overgrowth were treated by additional deployment of SEMS or plastic stent (PS). Biliary sludge inside the stents was eliminated by balloon retrieval. Reinterventions for both liver lobes were feasible by passing the guide wire inside the previously placed stents in three cases ( [Fig. 2a](#FI1351-2){ref-type="fig"} , [Fig. 2b](#FI1351-2){ref-type="fig"} , [Fig. 2c](#FI1351-2){ref-type="fig"} ). Five patients received additional chemotherapy (gemcitabine plus cisplatin). Median stent patency was 150 days during a mean follow-up period of 184 days (range: 37 -- 558; [Fig. 3](#FI1351-3){ref-type="fig"} ). Three patients developed self-limiting cholangitis without definite stent occlusion as late (\> 30 days) AEs. They were managed with conservative therapy ( [Table 3](#TB1351-3){ref-type="table"} ).

###### Demographic data on and outcome for each patient.

  Patient no.   Age (yr)   Gender   Diagnosis   Type of stenosis [1](#FN1351-2){ref-type="table-fn"}   Initial drainage (No. of stents)   Method (No. of stents)   Stent patency   Survival           
  ------------- ---------- -------- ----------- ------------------------------------------------------ ---------------------------------- ------------------------ --------------- ------------ ----- -------
   1            84         F        CC          IIIa                                                   ENBD (1)                           SBS + SIS (3)            150             Obstructed   447   Dead
   2            85         F        CC          IV                                                     EBS (2)                            SBS + SIS (3)            392             Patent       392   Dead
   3            74         M        CC          IV                                                     EBS (1) ENBD (1)                   SBS + SIS (3)            103             Patent       103   Dead
   4            66         F        CC          IIIa                                                   EBS (1) ENBD (1)                   SBS + SIS (3)            232             Obstructed   558   Alive
   5            79         F        CC          IV                                                     EBS (2)                            SBS + SIS (4)            124             Obstructed   143   Dead
   6            53         M        CC          IIIa                                                   EBS (1)                            SBS + SIS (3)             54             Patent        54   Alive
   7            80         M        GBC         IIIa                                                   ENBD (1)                           SBS + SIS (3)             70             Patent        70   Dead
   8            65         F        GBC         IIIa                                                   EBS (2)                            SBS + SIS (3)            104             Patent       104   Dead
   9            88         F        GBC         IIIa                                                   EBS (2)                            SBS + SIS (3)             28             Obstructed    69   Dead
  10            75         M        CCC         IV                                                     EBS (1) ENBD (1)                   SBS + SIS (3)             43             Patent        43   Dead
  11            82         M        HCC         IIIa                                                   EBS (3)                            SBS + SIS (4)             37             Patent        37   Dead

F, female; M, male; CC, cholangiocarcinoma; ENBD, endoscopic nasobiliary drainage; SBS, side-by-side; SIS, stent-in-stent; EBS, endoscopic biliary stenting; GBC, gall bladder carcinoma; CCC, cholangiocellular carcinoma; HCC, hepatocellular carcinoma.

Bismuth-Corlette classification

![ Reintervention for both liver lobes. **a** 0.025-inch guide wires were passed through the previously placed stents to both liver lobes. **b, c** Two additional SEMS were deployed inside the stents.](10-1055-a-0849-9334-i1351ei2){#FI1351-2}

![Stent patency (Kaplan-Meier).](10-1055-a-0849-9334-i1351ei3){#FI1351-3}

###### Outcomes.

                                              **Data**
  ------------------------------------------- -----------------
  Success rate                                
  Technical success (n, %)                    11, 100.0
  Clinical success (n, %)                     11, 100.0
  Stent obstruction (n, %)                    4, 36.4
  Cause of obstruction                        
  tumor ingrowth                              2, 18.2
  tumor overgrowth                            1, 9.1
  biliary sludge                              1, 9.1
  Reintervention (n, %)                       4, 36.4
  Type of reintervention                      
  SEMS                                        2, 18.2
  EBS                                         1, 9.1
  Balloon retrieval                           1, 9.1
  Reintervention for both liver lobes         3, 27.3
  Stent patency (days), median (95 % CI)      150 (42 -- 258)
  Overall survival (days), median (95 % CI)   104 (53 -- 155)
  Adverse events                              
  Early (≤ 30 days) (n, %)                    0, 0.0
  Late (\> 30 days) (n, %)                    3, 27.3
  Cholangitis                                 3, 27.3

CI, confidence interval.

Discussion
==========

Several studies have highlighted the advantages of SEMS compared with PS, and recent meta-analyses have shown that SEMS are associated with significantly higher successful drainage, fewer complications, longer stent patency, and longer patient survival in malignant hilar lesions [@JR1351-6] [@JR1351-7] .

Debate is ongoing regarding the range of drainage in cases with UMHBS [@JR1351-6] . The reason to support bilateral stent placement is based on the concept that draining a volume greater than 50 % of the liver is associated with effective drainage and prolonged survival [@JR1351-8] . In a recent randomized controlled trial comparing outcomes of bilateral and unilateral placement of SEMS for UMHBS, both procedures had similar technical success rates, but bilateral drainage resulted in fewer reinterventions and more durable stent patency [@JR1351-9] .

Regarding treatment for high-grade UMHBS, Kawamoto et al. [@JR1351-3] reported endoscopic three-branched partial SIS deployment of SEMS. In this method, two additional SEMS were deployed in the right anterior and posterior sectoral ducts through the mesh of the SEMS first placed in the left hepatic duct. Similarly, as a revisionary method, an additional third metal stent was deployed into a bilateral SIS configuration with cross-wired metal stents using this technique [@JR1351-4] .

With the advent of the 6-Fr delivery system, we deployed multiple SEMS endoscopically using a combination of the SBS and SIS method to treat high-grade UMHBS. This technique has the following advantages. First, it may be easy to deploy the third stent. Using this method, the stent delivery system passes through the mesh of only one stent to deploy the third stent. Second, alignment of the distal stent edges using the SBS method may permit passage of the guide wire through the stents to both liver lobes for selective reintervention. Although reinterventions for both liver lobes were feasible in three of four cases in our study, they are still difficult after SBS stent placement above the papilla using laser-cut SEMS. Actually, we failed to pass a guide wire through the occluded stent to the left lobe in one case. It might be helpful to align the distal stent edges in the duodenum for future access to reintervention.

Median stent patency was 150 days in our study. We used 8-mm metal stents. Compared with recent reports, stent patency in this study may be short. We speculate that stent patency might be underestimated because our cases included patients with poor prognosis and serious comorbidities and any death before stent occlusion was treated as censored data.

This study is limited by the small number of cases in a single center. The noncomparative nature of this study is also a limitation. Furthermore, whether SBS or SIS is the preferred method for bilateral SEMS remains unclear. Nevertheless, high technical and clinical success rates, low incidence of AEs, and good recovery from stent occlusion were observed in this study. We expect that the procedure shown in this study will become an option for treating high-grade UMHBS.

Conclusion
==========

In conclusion, it is speculated that some cases with high-grade UMHBS require placement of multiple stents (≥ 3) to control jaundice and cholangitis. Employing the combination of SBS and SIS methods may facilitate the endoscopic deployment of multiple SEMS for such cases.
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